@article{ffaf807f2ea344e5afd8ddfab300ddf3,
title = "Older versus middle-aged adults with schizophrenia: Executive functioning and community outcomes",
keywords = "Community functioning, Executive function, Functional capacity, Older adults, Schizophrenia",
author = "Anjana Muralidharan and Anastasia Finch and Bowie, {Christopher R.} and Harvey, {Philip D.}",
note = "Funding Information: This research was funded by NIMH grant MH 63116 to Dr. Harvey and the U.S. Department of Veterans Affairs VISN 3 MIRECC . Dr. Muralidharan is supported by VA Rehabilitation Research and Development Career Development Award IK2RX002339 . This manuscript is result of work supported with resources and the use of facilities at the U.S. Department of Veterans Affairs VISN 5 MIRECC. All authors who contributed to this paper are listed as authors. No professional medical writer was involved in any portion of the preparation of the manuscript. This work reflects the authors{\textquoteright} personal views and in no way represents the official view of the Department of Veterans Affairs or the U.S. Government. Appendix A Funding Information: This research was funded by NIMH grant MH 63116 to Dr. Harvey and the U.S. Department of Veterans Affairs VISN 3 MIRECC. Dr. Muralidharan is supported by VA Rehabilitation Research and Development Career Development Award IK2RX002339. This manuscript is result of work supported with resources and the use of facilities at the U.S. Department of Veterans Affairs VISN 5 MIRECC. All authors who contributed to this paper are listed as authors. No professional medical writer was involved in any portion of the preparation of the manuscript. This work reflects the authors? personal views and in no way represents the official view of the Department of Veterans Affairs or the U.S. Government. Funding Information: Dr. Muralidharan and Dr. Finch have no conflicts of interest to report with regard to this work. Dr. Harvey has received consulting fees or travel reimbursements from Alkermes, Boehringer Ingelheim, Intra-Cellular Therapies, Minerva Pharma, Otsuka America, Regeneron Pharma, Roche Pharma, Sunovion Pharma, Takeda Pharma, and Teva during the past year. He receives royalties from the Brief Assessment of Cognition in Schizophrenia. He is chief scientific officer of i-Function, Inc. He has a research grant from Takeda and from the Stanley Medical Research Foundation. Dr. Bowie has received consulting fees from Boehringer Ingelheim, Lundbeck Pharma, Otsuka Digital Health, and Takeda Pharma. He has received grant support from Lundbeck, Pfizer, and Takeda. ",
year = "2020",
month = feb,
doi = "10.1016/j.schres.2019.11.001",
language = "English (US)",
volume = "216",
pages = "547--549",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
}
